Results 131 to 140 of about 578 (168)
Omalizumab Updosing for Better Disease Control in Chronic Spontaneous Urticaria Patients [PDF]
International Archives of Allergy and Applied Immunology, 2018 The recommended dose of omalizumab for the treatment of chronic spontaneous urticaria (CSU) is 300 mg every 4 weeks, but there is no recommendation for patients who do not benefit from this dose.
Ana M Gimenez-Arnau +2 more
exaly +5 more sources
A Safe and Effective 7 Week Updosing Protocol for Bee and Wasp Venom Immunotherapy
Clinical and Experimental AllergyHymenoptera venom immunotherapy (VIT) is the only effective treatment to prevent systemic reactions (SR) and anaphylaxis from insect stings. The efficacy of VIT is well established, with success rates of 77%–84% for bee venom and 90%–95% for wasp venom ...
Shuaib Nasser, Priya Sellaturay
exaly +6 more sources
Allergy: European Journal of Allergy and Clinical ImmunologyBackground: Limited information is available on the use of omalizumab (OMA) updos- ing since its introduction as a second- line therapy in chronic spontaneous urticaria (CSU) in 2014.
Hacard Florence +2 more
exaly +7 more sources
Allergologia Et Immunopathologia, 2006 Due to optimal safety of sublingual immunotherapy (SLIT), it was suggested that a slow up-dosing phase maybe not necessary, and therefore the treatment will be more patient-friendly, avoiding dosing mistakes.Twenty adult patients suffering allergic rhinitis due to Parietaria, were enrolled.
Giorgio Walter Canonica +2 more
exaly +4 more sources
Updosing of Antihistamines to Improve Control of Chronic Urticaria
Indian Journal of Dermatology, Venereology and Leprology, 2010 Kiran Godse, Kiranv Godse
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Indian Journal of Skin Allergy, 2022
Objectives: In patients not responding to standard dosages of second-generation antihistamines (SGAHs), updosing up to 4-fold is recommended. Even though SGAHs are safe, the concerns regarding their safety after updosing still remain and the studies directly comparing the updosing of different SGAHs are lacking thus making the choice of drug difficult.
Dhiraj Dhoot +2 more
exaly +2 more sources
Objectives: In patients not responding to standard dosages of second-generation antihistamines (SGAHs), updosing up to 4-fold is recommended. Even though SGAHs are safe, the concerns regarding their safety after updosing still remain and the studies directly comparing the updosing of different SGAHs are lacking thus making the choice of drug difficult.
Dhiraj Dhoot +2 more
exaly +2 more sources
Once Daily Sublingual Immunotherapy Without Updosing – A New Treatment Schedule
International Archives of Allergy and Applied Immunology, 2006<i>Background:</i> Treatment regimens with specific immunotherapy include updosing. Due to excellent tolerance of sublingual immunotherapy (SLIT), it was hypothesized that administration of once-daily SLIT could be initiated safely without updosing. The objective was to evaluate tolerability of SLIT administered once daily without updosing.
M Boquete, A I Tabar, A I Tabar
exaly +3 more sources
Comparative Efficacy of Non-Sedating Antihistamine Updosing in Patients With Chronic Urticaria [PDF]
World Allergy Organization Journal, 2014 Urticaria and angioedema lasting more than 6 weeks have been designated as chronic urticaria (CU). It encompasses two major subtypes: chronic spontaneous urticaria (CSU) (previously known as chronic idiopathic urticaria) (CIU) and chronic inducible urticaria.
Anahí Yáñez +2 more
exaly +3 more sources
Journal of Cutaneous Medicine and Surgery, 2019
Background: Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). Studies investigating the use of higher doses of omalizumab in patients unresponsive to regular doses are limited. Objectives: This study aims to
Andac Salman, Elif Comert
exaly +4 more sources
Background: Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). Studies investigating the use of higher doses of omalizumab in patients unresponsive to regular doses are limited. Objectives: This study aims to
Andac Salman, Elif Comert
exaly +4 more sources
British Journal of Dermatology, 2016
There is a lack of large, randomized, double-blind studies that address antihistamine updosing for chronic spontaneous urticaria (CSU). The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.
Marta Ferrer, Francisco Guillen-Grima
exaly +3 more sources
There is a lack of large, randomized, double-blind studies that address antihistamine updosing for chronic spontaneous urticaria (CSU). The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.
Marta Ferrer, Francisco Guillen-Grima
exaly +3 more sources